Oncology

T-cells modified to express dominant-negative TGF-β receptor type 2 overcame cancer cell defenses.

An obesity drug may reduce the risk of metastatic prostate cancer.

Diabetes is the seventh-leading cause of death in the United States.

Gene expression may lead to castration-resistant prostate cancer.

Cancer registrars systematically capture all types of data about cancer and tumor diseases.

Patients with both hepatitis C and type 2 diabetes can develop fibrosis, steatosis, hepatocellular carcinoma, and resistance to antiviral treatment.

Court invalidates patent for abiraterone acetate (Zytiga).

Kohei Shitara, MD, Department of Gastrointestinal Oncology of National Cancer Center Hospital East, Japan, discusses the importance of the REVERCE clinical trial for specialty pharmacists.

Prior treatment with sorafenib followed by pembrolizumab (Keytruda) shows promising progression-free survival and overall survival in patients with advanced hepatocellular carcinoma.

Cetuximab (Erbitux) with pembrolizumab (Keytruda) shows promise in patients with mCRC.

Induction therapy shows the potential to achieve disease control in patients with locally advanced pancreatic cancer.

A novel CTC assay showed up to 88% accuracy detecting precancerous and cancerous colorectal lesions.

Nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy) induced responses in patients with heavily pretreated gastrointestinal stromal tumors.

The addition of ramucirumab did not improve overall survival in patients with HER2-negative gastric cancer.

Through the ages, cancer’s reputation has been notorious.

Three genes may increase the risk of breast and ovarian cancers in patients with BRCA mutations.

A majority of patients with hepatitis C experience disorders outside of the liver that are related to the virus.

In the United States, cancer is responsible for more than half a million deaths annually and is the second-leading cause of death, after cardiovascular disease

A combination VEGFR-2 inhibitor plus an anti–PD-L1 agent demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

Cabometyx found to improve median overall survival by 2.2 months in patients with previously treated advanced hepatocellular carcinoma.

Pembrolizumab (Keytruda) combination therapy may improve outcomes for patients with metastatic non-small cell lung cancer.

More than 60% of very elderly patients with stage 3 lung cancer did not receive treatment.

CDC notes link between jump in acute HCV cases and admissions to substance use disorder treatment facilities for opioid injections.

Patients with a high risk of recurrent breast cancer may not receive chemotherapy.

Afatinib (Gilotrif) found to improve overall survival among patients with EGFR-mutated non-small cell lung cancer.

Automated HCV antigen testing has a much faster turnaround time and lower costs.

The Maraba virus combined with an immune checkpoint inhibitor increased triple-negative breast cancer survival in mice.

Thus far there is no intervention that clearly reduces the risk of HCV infection from a mother to her child.

Based on the outcomes of Checkmate-238, the Food and Drug Administration approved nivolumab as adjuvant therapy for the treatment of melanoma.

Olaparib (Lynparza) is indicated to treat HER2-negative metastatic breast cancer with BRCA mutations.